Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E10.35 EPS (ttm)3.61 Insider Own8.91% Shs Outstand26.55M Perf Week-2.02%
Market Cap999.86M Forward P/E- EPS next Y-3.33 Insider Trans-0.63% Shs Float24.34M Perf Month16.21%
Income99.33M PEG- EPS next Q-0.99 Inst Own95.81% Short Float17.95% Perf Quarter63.12%
Sales292.96M P/S3.41 EPS this Y-609.35% Inst Trans-0.13% Short Ratio11.05 Perf Half Y14.54%
Book/sh10.48 P/B3.57 EPS next Y-86.63% ROA26.44% Short Interest4.37M Perf Year112.86%
Cash/sh12.98 P/C2.88 EPS next 5Y- ROE46.66% 52W Range14.21 - 41.68 Perf YTD18.68%
Dividend Est.- P/FCF7.54 EPS past 5Y- ROI30.37% 52W High-10.22% Beta2.63
Dividend TTM- Quick Ratio4.49 Sales past 5Y393.55% Gross Margin- 52W Low163.34% ATR (14)2.02
Dividend Ex-Date- Current Ratio4.49 EPS Y/Y TTM167.49% Oper. Margin43.74% RSI (14)56.29 Volatility4.48% 5.57%
Employees170 Debt/Eq0.18 Sales Y/Y TTM468.86% Profit Margin33.90% Recom1.30 Target Price66.33
Option/ShortYes / Yes LT Debt/Eq0.17 EPS Q/Q54.18% Payout0.00% Rel Volume0.86 Prev Close37.44
Sales Surprise184.75% EPS Surprise63.94% Sales Q/Q224.45% EarningsMar 07 AMC Avg Volume395.32K Price37.42
SMA203.39% SMA5012.64% SMA20030.66% Trades Volume339,805 Change-0.05%
Date Action Analyst Rating Change Price Target Change
Dec-13-23Initiated Canaccord Genuity Buy $90
Jul-24-23Initiated William Blair Outperform $71
May-11-23Upgrade H.C. Wainwright Neutral → Buy $19 → $51
Nov-14-22Resumed Wells Fargo Overweight $35
Nov-10-22Downgrade Robert W. Baird Neutral → Underperform $18
Nov-03-22Upgrade Citigroup Neutral → Buy $22 → $35
Nov-02-22Upgrade Barclays Underweight → Equal Weight $16 → $25
Aug-10-22Downgrade Raymond James Mkt Perform → Underperform
Jul-19-22Resumed Cantor Fitzgerald Overweight $86 → $39
May-11-22Upgrade Robert W. Baird Underperform → Neutral $21 → $18
Feb-22-24 08:30AM
Feb-20-24 09:00AM
Feb-05-24 08:30AM
Jan-23-24 04:16AM
Jan-05-24 01:17PM
08:00AM Loading…
Dec-21-23 08:00AM
Dec-17-23 12:03PM
Dec-13-23 10:39PM
Dec-08-23 10:13AM
Dec-04-23 08:30AM
Nov-28-23 08:05AM
Nov-27-23 08:30AM
Nov-15-23 01:26PM
05:19PM Loading…
Nov-14-23 05:19PM
Oct-25-23 04:01PM
Oct-23-23 04:01PM
Oct-04-23 11:01PM
Sep-26-23 08:30AM
Sep-19-23 08:30AM
Sep-05-23 08:30AM
Aug-17-23 08:30AM
Aug-14-23 09:00AM
Aug-10-23 07:15AM
Aug-08-23 02:39PM
01:09PM Loading…
Aug-07-23 07:50PM
Aug-04-23 09:21AM
Jul-28-23 05:14PM
Jul-24-23 04:01PM
Jul-18-23 06:22AM
Jul-16-23 08:18PM
Jul-14-23 02:36PM
Jul-05-23 06:15AM
Jun-14-23 08:24AM
Jun-01-23 08:30AM
May-18-23 07:16AM
May-12-23 02:04AM
May-09-23 05:35PM
May-08-23 07:43AM
Apr-28-23 01:39PM
Apr-26-23 08:30AM
Apr-17-23 07:10AM
Mar-30-23 08:29AM
Mar-29-23 11:45AM
Mar-28-23 05:15PM
Mar-27-23 09:11AM
Mar-23-23 06:18AM
Mar-07-23 08:00AM
Feb-06-23 08:30AM
Jan-31-23 08:30AM
Dec-28-22 11:35AM
Dec-19-22 08:30AM
Dec-13-22 08:30AM
Dec-12-22 08:30AM
Dec-01-22 10:23AM
Nov-16-22 05:24AM
Nov-12-22 07:04AM
Nov-09-22 05:25PM
Nov-07-22 05:00PM
Nov-04-22 05:46AM
Nov-02-22 12:00PM
Nov-01-22 06:05PM
Oct-26-22 04:30PM
Oct-18-22 08:05AM
Sep-27-22 06:00PM
Sep-22-22 12:28PM
Sep-07-22 06:44AM
Sep-01-22 04:00PM
Aug-31-22 04:00PM
Aug-18-22 12:00PM
Aug-11-22 06:08AM
Aug-09-22 05:15PM
Aug-01-22 04:00PM
Jul-21-22 08:23AM
Jun-21-22 08:00PM
Jun-10-22 06:38AM
May-20-22 08:00PM
May-11-22 06:19AM
May-09-22 05:15PM
Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chivukula PadChief Scientific Officer & COONov 01Sale18.725,00093,602499,448Nov 03 04:30 PM
Chivukula PadChief Scientific Officer & COOOct 02Sale25.615,000128,062504,448Oct 04 04:06 PM
Chivukula PadChief Scientific Officer & COOSep 01Sale31.455,000157,264509,448Sep 05 04:05 PM
Chivukula PadChief Scientific Officer & COOAug 01Sale34.915,000174,550514,448Aug 03 04:15 PM
Kummerfeld Keith CSee RemarksJul 14Option Exercise8.966,96862,4087,918Jul 18 06:50 PM
Chivukula PadChief Scientific Officer & COOJul 14Sale35.0125,000875,250519,448Jul 18 06:50 PM
Kummerfeld Keith CSee RemarksJul 14Sale35.006,968243,880950Jul 18 06:50 PM
Chivukula PadChief Scientific Officer & COOJul 03Sale28.755,000143,750544,448Jul 07 06:01 AM
Chivukula PadChief Scientific Officer & COOJun 01Sale27.165,000135,800549,448Jun 05 04:07 PM
Chivukula PadChief Scientific Officer & COOMay 11Sale30.247,925239,652554,448May 12 04:05 PM
Chivukula PadChief Scientific Officer & COOMay 10Sale30.0017,075512,250562,373May 12 04:05 PM
Chivukula PadChief Scientific Officer & COOMay 01Sale25.935,000129,650579,448May 03 04:08 PM
Kummerfeld Keith CSee RemarksApr 18Option Exercise8.966,96862,4087,918Apr 19 04:57 PM
Kummerfeld Keith CSee RemarksApr 18Sale28.186,968196,358950Apr 19 04:57 PM
Chivukula PadChief Scientific Officer & COOApr 03Sale25.385,000126,900584,448Apr 05 08:47 PM
Chivukula PadChief Scientific Officer & COOMar 06Sale16.075,00080,350589,448Mar 08 09:34 PM